Online inquiry

IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6707MR)

This product GTTS-WQ6707MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Colorectal Cancer (CRC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6707MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4069MR IVTScrip™ mRNA-Anti-IGF, BI 836(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BI 836
GTTS-WQ11221MR IVTScrip™ mRNA-Anti-pcrV&psl, MEDI3902(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI3902
GTTS-WQ14290MR IVTScrip™ mRNA-Anti-CSF1R, RG7155(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RG7155
GTTS-WQ11313MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, MEDI-522(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MEDI-522
GTTS-WQ7043MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Fab-12 variant Y0317
GTTS-WQ9115MR IVTScrip™ mRNA-Anti-MUC1, IMGN242(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMGN242
GTTS-WQ5072MR IVTScrip™ mRNA-Anti-C5, CaCP-29(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CaCP-29
GTTS-WQ14313MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RG-7221
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW